Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population

CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042

Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research